Gynecology Beyond Gender: Cervical Cancer Screening in Transgender Men in France

NCT05924217 | Active Not Recruiting

• 1 other identifier: LOCAL/2023/thése/IJ-01
• Study Type: observational
• Target: 300
• Locations: 1 country
• Sites: 1

Brief Summary

In France, cervical cancer screening is the subject of a national screening programme organized for all asymptomatic individuals aged 25 to 65 years with a cervix. The latter contributes greatly to the prevention and early treatment of this disease, whose public health challenge is recognized worldwide. One of the objectives of this programme is to reduce inequalities in access. Transgender men, i.e. individuals assigned to the female gender at birth but identifying with the male gender, are concerned by this screening as long as they still have a cervix, according to the same modalities as for cisgender women. However, they are often excluded from health care, including organized screening programs. Gender change in civil status is one of the obstacles. The provision of gynaecological care is sometimes inadequate. The lack of knowledge of health professionals and the problems of discrimination that transgender people may face reduce the chances of having equitable access. This survey aims to explore the perception that transgender men have of cervical cancer screening and to identify the challenges they face, the obstacles and the levers to access this prevention program.

Conditions

Cervical Cancer; Transgender Persons; Health Services for Transgender Persons

Outcome Measures

Primary Outcomes (1)

• prevalence of transgender men who have ever been screened for cervical cancer in their lifetime

  answer yes to the question "Have you ever been screened for cervical cancer in your lifetime?"

  At study entry, basline (no follow-up)

Secondary Outcomes (1)

• prevalence of transgender men who feel concerned about cervical cancer screening

  At study entry, basline (no follow-up)

Interventions

Survey questionnaire OTHER

This survey aims to explore the perception that transgender men have of cervical cancer screening and to identify the challenges they face, the obstacles and the levers to access this prevention program.

Eligibility Criteria

• Age: 25 Years - 65 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Transgender men, i.e. individuals assigned the female gender at birth but identifying with the male gender, who retained the cervix

You may qualify if:

• transgender male (assigned female at birth but identifying as male)
• aged 25 to 65 years
• Having retained her cervix
• Having had sex before.

You may not qualify if:

• Under 25 and over 65
• Not having retained his cervix
• History of cancerous lesion of the cervix

Sponsors & Collaborators

• Centre Hospitalier Universitaire de Nīmes: lead

Study Sites (1)

CHU de Nîmes

Nîmes, 30900, France

Location

MeSH Terms

Conditions

Uterine Cervical Neoplasms

Interventions

Surveys and Questionnaires

Condition Hierarchy (Ancestors)

Uterine Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Uterine Cervical Diseases; Uterine Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases

Intervention Hierarchy (Ancestors)

Data Collection; Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Officials

• ingrid JULIER

  Centre Hospitalier Universitaire de Nīmes

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 12, 2023
• First Posted: June 29, 2023
• Study Start: January 2, 2024
• Primary Completion: January 1, 2025
• Study Completion (Estimated): June 30, 2026
• Last Updated: November 17, 2025

Record last verified: 2025-11

Locations

FR (1)